Bio-Rad buys neonate screening test company:
This article was originally published in Clinica
Bio-Rad Laboratories is buying Perth, Scotland-based Quantase, which develops screening tests for neonates, a market estimated at more than $100 million worldwide, with a 10% growth rate. The deal, for an undisclosed amount, strengthens Hercules, California-based Bio-Rad's position in the genetic screening market. The company notes that genetic screening of newborns is compulsory in the US.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.